申请人:Astra Pharmaceuticals Ltd.
公开号:US05721219A1
公开(公告)日:1998-02-24
There are disclosed compounds of formula I, ##STR1## wherein R.sup.1 and R.sup.2 independently represent hydrogen or halogen, R.sup.3 and R.sup.4 independently represent phenyl, or alkyl C.sub.1-6, optionally substituted by one or more substituents selected from OR.sup.5, alkylthio C.sub.1-6, NR.sup.6 R.sup.7, phenyl, COOR.sup.8 and halogen, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 independently represent hydrogen or alkyl C.sub.1-6, and X represents an acidic moiety, and pharmaceutically acceptable salts thereof. Processes for their production and pharmaceutical compositions and methods of treatment involving their use are also described.
公式I的化合物已被披露,其中R.sup.1和R.sup.2独立地代表氢或卤素,R.sup.3和R.sup.4独立地代表苯基或烷基C.sub.1-6,可以选择地被一个或多个取代基所取代,所选取代基来自OR.sup.5,烷基硫基C.sub.1-6,NR.sup.6 R.sup.7,苯基,COOR.sup.8和卤素,R.sup.5,R.sup.6,R.sup.7和R.sup.8独立地代表氢或烷基C.sub.1-6,X代表酸性基团,以及其药学上可接受的盐。还描述了它们的生产过程、药物组合物和涉及其使用的治疗方法。